Skip to main
PAVM

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. demonstrated a steady increase in the processing of EsoGuard tests, reflecting the company's potential for revenue growth, with tests increasing from 2,756 in Q2 to 2,841 in Q3. The current valuation of PAVmed is viewed as attractive, with expectations for substantial growth in its commercialized products, particularly EsoGuard and others, anticipated in 2025 and 2026. This favorable outlook is underpinned by the strong momentum in testing volume and the ongoing advancement of the company’s medical technology pipeline, which balances inherent risks with significant upside potential.

Bears say

PAVmed Inc reported a pro forma net loss of $0.8 million with an earnings per share (EPS) of $(0.05), which is a slight improvement compared to the previously estimated losses but still reflects weak financial performance. The company's revenue generation remains low, particularly as its EsoGuard tests declined from 3,034 in Q1 to 2,756 in Q2, indicating a troubling downward trend in test volumes. Furthermore, the company faces significant risks, including balance sheet and liquidity concerns, regulatory hurdles, and challenges in commercialization, which amplify the negative outlook on its stock performance.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.